Teriparatide - Azelon Pharmaceuticals

Drug Profile

Teriparatide - Azelon Pharmaceuticals

Alternative Names: Parathyroid-hormone-1-34 - Azelon Pharmaceuticals; PTH 1-34 - Azelon; Teriparatide injection - Azelon Pharmaceuticals; Teriparatide intranasal - Azelon Pharmaceuticals; ZT-034

Latest Information Update: 18 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Zelos Therapeutics Inc
  • Developer Azelon Pharmaceuticals
  • Class Osteoporosis therapies; Peptide hormones; Skin disorder therapies
  • Mechanism of Action Osteogenesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Postmenopausal osteoporosis

Most Recent Events

  • 27 Aug 2015 Aegis Pharmaceuticals has patent protection for metered nasal spray parathyroid hormone peptide drug formulations in USA
  • 21 Oct 2013 Biomarkers information updated
  • 02 May 2012 Azelon Pharmaceuticals completes a phase IIa trial (nasal spray) in Osteoporosis in the US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top